Reliance Global Group Inc. Q4 FY2025 earnings call

• 2025 was a year of reshaping the company, focusing on strengthening the business foundation and executing a strategy with two pillars: insurance and InsurTech platform for stability and EZRA International Group with Scale51 model for entering emerging tech sectors. • Scale51 model identifies innovative tech companies, acquires ownership positions and supports growth. • Insurance and InsurTech operations generate recurring revenue, with RELI Exchange's partner network expanding. • Took steps to strengthen balance sheet and simplify structure by monetizing non-core operations. • Announced investments in Enquantum and agreement to acquire majority stake in Scentech Medical. • Transitioned NASDAQ ticker symbol from RELI to EZRA.

The insurance and InsurTech operations generated more than $12 million in commission income in 2025. The insurance and InsurTech platform serves as the operational backbone, with personal lines, property and casualty premiums generating increasing approximately 36% year-over-year and policies written during the most recent health insurance open enrollment increasing approximately 72% since acquiring RELI Exchange in 2022, with the partner network expanding from roughly 65 agencies to approximately 250. The Scale51 model is focused on identifying innovative technology companies in sectors like cybersecurity, artificial intelligence, fintech and digital health, with initial transactions like investment in Enquantum and agreement to acquire majority stake in Scentech Medical.

• Expect positive progress with Scale51 strategy, including milestones to be achieved for investments. • Enquantum has potential to generate revenue even later in 2025. • Scentech Medical's non-invasive breath analysis technology is expected to contribute to future growth and rewards.

• Forward-looking statements are subject to risks, uncertainties and assumptions as described in the company's Form 10-K, including that forward-looking events and circumstances discussed may not occur and actual results could differ materially from those anticipated.

Q: Can you share more about what investors should expect from the Scale51 strategy over the next 6 to 12 months?

A: Focus on companies showing close to revenue, off to good start with Enquantum, milestones need to be achieved for payments/investments, look forward to more as milestones are reached.

Q: Where is Enquantum currently in terms of product development and commercialization and what time line for revenue?

A: Revenue possible even within the year, later this year, team working towards revenue, quantum computing is extremely fast and crucial for post-quantum encryption, due diligence team impressed by Enquantum's team.

Q: Can you expand on what makes Scentech's approach unique and differentiates it from other diagnostic technologies?

A: Focused on pancreatic cancer, using non-invasive breath analysis technology with biomarkers in human breast, early detection is key, due diligence team impressed, early detection saves lives and differentiates it.